Search bioRxiv⌕ Search

Biology subjects

Owens, J. M.

Publications and source records attributed to Owens, J. M..

2 recordsLinked to original sources

Interleukin-6 Concentration Regulates the Neutrophil Response to Diverse Bacteria

Neutrophils are critical mediators of the innate immune response, and their antimicrobial functions are tightly regulated by a myriad of cytokines. Interleukin-6 (IL-6) is known to be essential for an effective immune response; however, how varying IL-6 concentrations affect the neutrophil response remains poorly understood. Because IL-6 concentrations can vary greatly across different disease states, we investigated the concentration dependent effects of IL-6 on the neutrophil response to diverse bacterial pathogens using an infection-on-a-chip microfluidic device. We found that a high exogenous IL-6 concentration (100 ng/mL) reduced neutrophil extravasation, migration speed, and displacement compared to conditions without exogenous IL-6. In contrast, a lower exogenous IL-6 concentration (10 ng/mL) produced pathogen-specific effects on neutrophil extravasation: exogenous IL-6 increased neutrophil extravasation in response to Pseudomonas aeruginosa, did not change in response to Listeria monocytogenes, and decreased in response to Staphylococcus aureus relative to controls. We then determined the potential endothelial cell contributions to these responses. We found that increasing IL-6 concentration resulted in decreased VE-cadherin expression and that 100 ng/mL exogenous IL-6 resulted in lower ICAM-1 expression than 10 ng/mL exogenous IL-6 in an endothelium exposed to P. aeruginosa. Together, these results demonstrate that IL-6 exerts concentration- and pathogen-dependent effects on neutrophil recruitment and migration, supporting a dual role for IL-6 as both pro-inflammatory and anti-inflammatory, with higher IL-6 concentrations resulting in a more anti-inflammatory neutrophil response.

immunology↗

Antibodies blocking PlGF or VEGF interactions with the NRP1 receptormediate anti-proliferative effects

Antibodies blocking the function of vascular endothelial growth factor A (VEGFA) remain a promising therapeutic strategy, especially when combined with check-point inhibitors, but their efficacy is limited by tumor resistance. This can occur via multiple mechanisms, including upregulation of placental growth factor 2 (PlGF-2), an alternative ligand for VEGF receptor 1 (VEGFR1) and neuropilin receptor 1 (NRP1). Activity of both growth factors is mediated by interactions with multiple receptors and extra-cellular matrix components, which complicates efforts to understand their contributions to cancer progression. To complement existing antibodies, we discovered those blocking interactions between PlGF-2 or VEGFA and their shared NRP1 receptor in the presence of heparin. Limiting angiogenesis to promote vascular normalization is one mechanism of anti-VEGF protection; here, anti-VEGFA antibodies blocking interactions with VEGFR1 and NRP1 reduced HUVEC tube formation in a physiological angiogenesis model. By contrast, antibodies binding PlGF-2 or VEGFA to block NRP1 significantly reduced proliferation of Caki-I kidney carcinoma cells in vitro, indicating this receptor mediates additional effects. Interestingly, one antibody exhibited dual-reactive binding to VEGFA and PlGF-2, suggesting a novel therapeutic strategy to prevent PlGF-driven VEGF-resistance. Overall, these antibodies define new mechanisms to disrupt PlGF activity and support a role for NRP1 in cell proliferation. Key ResultsO_LINew antibodies binding VEGFA or PlGF selectively block NRP1-receptor interactions. C_LIO_LIAntibody blockade of VEGFA binding to NRP1 reduced HUVEC angiogenesis. C_LIO_LIBlocking growth factor interactions with NRP1 reduced Caki-I renal carcinoma proliferation. C_LIO_LIIdentified an antibody with dual-reactive binding to VEGFA and PlGF. C_LI

biochemistry↗